{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Completed",
      "city": "Jersey City",
      "state": "NJ",
      "country": "United States",
      "classification": "Class I",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "93113",
      "recalling_firm": "Scynexis, Inc.",
      "address_1": "1 Evertrust Plz Fl 13",
      "address_2": "N/A",
      "postal_code": "07302-3051",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "E-Mail",
      "distribution_pattern": "Nationwide in the US.",
      "recall_number": "D-0042-2024",
      "product_description": "BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302  NDC 75788-115-04",
      "product_quantity": "17,376",
      "reason_for_recall": "Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).",
      "recall_initiation_date": "20230925",
      "center_classification_date": "20231006",
      "report_date": "20231018",
      "code_info": "Lot# LF21000008, Exp. 11/30/2023         Lot# LF22000051, Exp. 11/30/2025"
    }
  ]
}